Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US7862817 | NA | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
Jun, 2025
(1 year, 7 months from now) |
Ingredients: PERTUZUMAB
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic